Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.

Kim JY, Lee SS, Byun JH, Kim SY, Park SH, Shin YM, Lee MG.

AJR Am J Roentgenol. 2013 Aug;201(2):322-31. doi: 10.2214/AJR.12.9478.

PMID:
23883212
2.

Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.

Gupta RT, Iseman CM, Leyendecker JR, Shyknevsky I, Merkle EM, Taouli B.

AJR Am J Roentgenol. 2012 Jul;199(1):35-43. doi: 10.2214/AJR.11.7757.

PMID:
22733891
3.

Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.

Choi JY, Kim MJ, Park YN, Lee JM, Yoo SK, Rha SY, Seok JY.

AJR Am J Roentgenol. 2011 Aug;197(2):399-405. doi: 10.2214/AJR.10.5439.

PMID:
21785086
4.

Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.

Kim SY, Wu EH, Park SH, Wang ZJ, Hope TA, Yee J, Zhao LQ, Chang WC, Yeh BM.

Abdom Radiol (NY). 2016 Aug;41(8):1522-31. doi: 10.1007/s00261-016-0703-1.

5.

Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.

Davenport MS, Caoili EM, Kaza RK, Hussain HK.

Radiology. 2014 Jul;272(1):123-31. doi: 10.1148/radiol.14132269. Epub 2014 Mar 8.

PMID:
24617733
6.

Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.

Goshima S, Kanematsu M, Watanabe H, Kondo H, Mizuno N, Kawada H, Shiratori Y, Onozuka M, Moriyama N, Bae KT.

Eur J Radiol. 2011 Aug;79(2):e108-12. doi: 10.1016/j.ejrad.2011.04.041. Epub 2011 May 17.

PMID:
21592707
7.
8.

Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.

Choi SH, Lee JM, Yu NC, Suh KS, Jang JJ, Kim SH, Choi BI.

AJR Am J Roentgenol. 2008 Aug;191(2):529-36. doi: 10.2214/AJR.07.2565.

PMID:
18647927
9.

Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.

Kim HJ, Kim BS, Kim MJ, Kim SH, de Campos RO, Hernandes M, Semelka RC.

J Magn Reson Imaging. 2013 Apr;37(4):903-8. doi: 10.1002/jmri.23874. Epub 2012 Oct 12.

PMID:
23065959
10.

Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.

Gupta RT, Marin D, Boll DT, Husarik DB, Davis DE, Feuerlein S, Merkle EM.

Eur J Radiol. 2012 Oct;81(10):2457-62. doi: 10.1016/j.ejrad.2011.10.014. Epub 2011 Dec 3.

PMID:
22138122
11.

The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.

Kim JI, Lee JM, Choi JY, Kim YK, Kim SH, Lee JY, Han JK, Choi BI.

Invest Radiol. 2008 Mar;43(3):202-10. doi: 10.1097/RLI.0b013e31815d6929.

PMID:
18301317
13.

Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.

Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK.

Radiology. 2013 Feb;266(2):452-61. doi: 10.1148/radiol.12120826. Epub 2012 Nov 28.

PMID:
23192781
14.

Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition.

Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR.

Radiology. 2014 May;271(2):426-34. doi: 10.1148/radiol.13131988. Epub 2014 Jan 21.

PMID:
24475864
15.

Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.

Kim HY, Choi JY, Kim CW, Bae SH, Yoon SK, Lee YJ, Rha SE, You YK, Kim DG, Jung ES.

Liver Transpl. 2012 Jul;18(7):850-7. doi: 10.1002/lt.23426.

16.

Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique.

Goshima S, Kanematsu M, Kondo H, Watanabe H, Kawada H, Moriyama N, Bae KT.

AJR Am J Roentgenol. 2013 Sep;201(3):578-82. doi: 10.2214/AJR.12.10034.

PMID:
23971449
17.

Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.

Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW.

AJR Am J Roentgenol. 2011 Jul;197(1):W44-52. doi: 10.2214/AJR.10.5845.

PMID:
21700994
18.

Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results.

Nakamura Y, Toyota N, Date S, Oda S, Namimoto T, Yamashita Y, Beppu T, Awai K.

J Comput Assist Tomogr. 2011 Nov-Dec;35(6):723-7. doi: 10.1097/RCT.0b013e3182372c40.

PMID:
22082543
19.

Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?

Watanabe H, Kanematsu M, Goshima S, Yoshida M, Kawada H, Kondo H, Moriyama N.

AJR Am J Roentgenol. 2012 Mar;198(3):589-95. doi: 10.2214/AJR.11.6844.

PMID:
22357997
20.

Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.

Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, Bae KT.

Radiology. 2011 Apr;259(1):142-50. doi: 10.1148/radiol.10100621. Epub 2011 Jan 19.

PMID:
21248234

Supplemental Content

Support Center